Review Article
Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
Table 2
Ongoing treatment studies evaluating MoAb treatment in ovarian cancer patients.
| Protocol number | Disease stage | Target therapy | Treatment | Study phase | PI |
| NCT00565851 (GOG-213) | Recurrent | Bevacizumab | Arm I: | Phase III | Coleman RL, MD | Carboplatin + Paclitaxel/Docetaxel every 3 weeks | Arm II: | Carboplatin + Paclitaxel/Docetaxel + Bevacizumab every 3 weeks |
| NCT00483782 (ICON 7) | Primary | Bevacizumab | Arm I: | Phase III | Perren TJ, MD | Carboplatin + Paclitaxel for 6 cycles | Arm II: | Carboplatin + Paclitaxel + Bev for 6 cycles + Bev for 12 cycles |
| NCT00849667 | Recurrent | Farletuzumab | Arm I: | Phase III | Morphotek, Inc | Carboplatin + Taxane + Farletuzumab 1.25 mg/kg | Arm II: | Carboplatin + Taxane + Farletuzumab 2.5 mg/kg | Arm III: | Carboplatin + Taxane + Placebo |
| NCT00951496 | Primary | Bevacizumab | Arm I: | Phase III | Joan L. Walker, MD | Carboplatin + Paclitaxel + bevacizumab for 6 cycles + bev until progression/recurrence | Arm II: | Carboplatin + Paclitaxel + bevacizumab for 6 cycles | Arm III: | Carboplatin + Paclitaxel + bevacizumab for 6 cycles |
| NCT00976911 | Primary | Bevacizumab | Arm I: | Phase III | Hoffmann-La Roche | Topotecan + Paclitaxel + liposomal doxorubicin | Arm II: | Bevacizumab + Topotecan + Paclitaxel + liposomal doxorubicin |
| NCT01081262 | Primary | Bevacizumab | bevacizumab | Phase III | Martin E. Gore, MD | capecitabine | carboplatin | oxaliplatin | paclitaxel | Procedure: quality-of-life assessment |
| NCT01167712 | Primary | Bevacizumab | Arm I: Carboplatin + Paclitaxel | Phase III | John K. Chan, MD | Arm II: Carboplatin + Paclitaxel |
| NCT01239732 | Primary | Bevacizumab | Arm I: Carboplatin + Bevacizumab + Paclitaxel | Phase III | Hoffmann-La Roche |
|
|